In This Issue

• From the IASLC Tobacco Control Committee

Editorials

• Spotlight on Camrelizumab in Advanced Squamous Lung Cancer: Another Feather in the Cap of Chinese Checkpoint Inhibitors
• The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in the Therapy of Advanced NSCLC
• Is Hypofractionation a Good Idea in Radiotherapy for Locally Advanced NSCLC?

Editorial - Lung Cancer Worldwide

• Lung Cancer in Sudan

Controversies in Thoracic Oncology

• Chemotherapy D PD-1/PD-L1 Blockade Should Not Be the Preferred Option in the Neoadjuvant Therapy of NSCLC
• Chemotherapy D PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLC

Review Articles

• The 2021 WHO Classification of Tumors of the Heart

Original Articles

• NAVIGATE 24-Month Results: Electromagnetic Navigation Bronchoscopy for Pulmonary Lesions at 37 Centers in Europe and the United States
• Improving Outcomes in NSCLC: Optimum Dose Fractionation in Radical Radiotherapy Matters
• Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
• A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors
• Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease

Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology. The journal is interested in receiving manuscripts dealing with epidemiology, prevention, screening, early detection, staging, cure, and treatment of thoracic malignancies. Submissions on tobacco control and cessation are of interest, particularly where there is direct relevance to lung cancer epidemiology and therapeutic outcomes. The Journal also welcomes submissions on pathologic and histologic classification and novel imaging and bronchoscopic approaches. Submissions regarding novel systemic therapies, particularly in the fields of biomarker targets, genomics, immunology, and cellular therapies are of interest. Novel radiotherapy and surgical techniques are of interest. Submission of randomized phase II and phase III trials, as well as meta analyses of individual participant data, are encouraged. Basic science studies must have direct clinical and translational relevance.

Authors are also welcome to submit to the journal's open access companion title, JTO Clinical and Research Reports, which welcomes a range of manuscripts from subset analyses of published trials to high-quality case reports